Poseida Therapeutics Q1 2024 Adj EPS $(0.25) Beats $(0.42) Estimate, Sales $28.14M Beat $11.67M Estimate

5/14/24 4:26:40 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $PSTX alert in real time by email

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.42) by 40.48 percent. The company reported quarterly sales of $28.14 million which beat the analyst consensus estimate of $11.67 million by 141.22 percent. This is a 172.09 percent increase over sales of $10.34 million the same period last year.

Get the next $PSTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PSTX

Date	Price Target	Rating	Analyst
1/4/2023	$15.00	Buy	H.C. Wainwright
1/7/2022	$24.00	Overweight	Cantor Fitzgerald

More analyst ratings

$PSTX
Leadership Updates

Live Leadership Updates

MaxCyte Appoints Cynthia Collins to its Board of Directors
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe
10/15/24 8:05:00 AM ET
$CERT
$MXCT
$PSTX
Computer Software: Prepackaged Software
Technology
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024. Dr. Rizvi is a seasoned executive with over 20 years of experience across all stages of drug development, including clinical strategy, execution, and commercialization. "Syed brings to Poseida an impressive combination of industry leadership and highly specialized drug
3/25/24 4:05:00 PM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Poseida Therapeutics Announces Leadership Transition
Mark Gergen to assume role of Executive Chairman of the Board of Directors of Poseida; Kristin Yarema, Ph.D., currently President, Cell Therapy, to be appointed President and CEO SAN DIEGO, Oct. 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D., currently President, Cell Therapy, to the role of President and Chief Executive Officer, each expected to be effective January 1, 2024.
10/9/23 4:30:00 PM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology Advancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumors Virtual R&D Day featuring partner Astellas Pharma and Poseida's leadership and scientific teams to be held today at 10:00am ET / 7:00am PT SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cel
11/14/24 9:00:00 AM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
SAN DIEGO, Nov. 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences: Stifel 2024 Healthcare ConferenceDate: Monday, November 18, 2024Time: 10:20am ET Piper Sandler 36th Annual Healthcare ConferenceDate: Wednesday, December 4, 2024Time: 12:00pm ET Webcasts will be available on the Investors & Media
11/11/24 4:05:00 PM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T
11/7/24 4:05:00 PM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T
11/7/24 4:05:00 PM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting toxicities, low rates of CRS and ICANS all Grade 2 or less and no graft vs. host disease or Parkinsonism P-BCMA-ALLO1 was recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is being evaluated in a Phase 1/1b clinical trial in patients with relapsed/refractory multiple myeloma who have previously received three or more prior lines of therapy Company to host we
9/27/24 4:30:00 PM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that
9/5/24 9:00:00 AM ET
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Poseida Therapeutics Q1 2024 Adj EPS $(0.25) Beats $(0.42) Estimate, Sales $28.14M Beat $11.67M Estimate

Chat with this insight

Recent Analyst Ratings for $PSTX

$PSTX Leadership Updates

Live Leadership Updates

MaxCyte Appoints Cynthia Collins to its Board of Directors

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Poseida Therapeutics Announces Leadership Transition

$PSTX SEC Filings

Poseida Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 10-Q filed by Poseida Therapeutics Inc.

Poseida Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$PSTX Press Releases

Fastest customizable press release news feed in the world

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

$PSTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Poseida Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Poseida Therapeutics with a new price target

BTIG Research initiated coverage on Poseida Therapeutics with a new price target

$PSTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

$PSTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Schmid John P. was granted 19,650 shares, increasing direct ownership by 50% to 58,950 units (SEC Form 4)

Director Lloyd Marcea Bland was granted 19,650 shares, increasing direct ownership by 40% to 68,950 units (SEC Form 4)

Director Corning Luke was granted 19,650 shares, increasing direct ownership by 50% to 58,950 units (SEC Form 4)

$PSTX Financials

Live finance-specific insights

$PSTX Market Insights

Live Market Insights

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

12 Health Care Stocks Moving In Tuesday's After-Market Session

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Recent Analyst Ratings for
$PSTX

$PSTX
Leadership Updates

$PSTX
SEC Filings

$PSTX
Press Releases

$PSTX
Analyst Ratings

$PSTX
Large Ownership Changes

$PSTX
Insider Trading

$PSTX
Financials

$PSTX
Market Insights